Why the study?
Does Ile-Gln-Pro (IQP) reduce blood pressure in spontaneously hypertensive rats?
Does Ile-Gln-Pro (IQP) reduce blood pressure in spontaneously hypertensive rats?
The ACE inhibitory peptide Ile-Gln-Pro significantly reduces blood pressure and regulates renin-angiotensin system components in spontaneously hypertensive rats.
IQP shows BP-lowering effects in hypertensive rats; leaves open translation to human hypertension.
The antihypertensive effect of an angiotensin I-converting enzyme (ACE) inhibitory peptide Ile-Gln-Pro (IQP), whose sequence was derived from Spirulina platensis , was investigated in spontaneously hypertensive rats (SHRs) for 1 week. The weighted systolic blood pressure (SBP) and diastolic blood pressure (DBP) of the peptide IQP-treated group were significantly lower than those of the negative control group from the third and fourth days, respectively. Accompanying the blood pressure reduction, a significant regulation of the expression of major components of the renin-angiotensin system (RAS) was found in the treatment group, including downregulation of the mRNA levels of renin, ACE, and the angiotensin II type 1 (AT1) receptor in the kidney, as well as serum angiotensinogen (Ang), ACE, and angiotensin II (Ang II) concentrations. The treatment group also showed upregulation of mRNA expression of the angiotensin II type 2 (AT2) receptor in the kidney. Our findings suggested that IQP might be of potential use in the treatment of hypertension.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2010) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: